EGF R Signaling Pathway

A complex signaling cascade that modulates cell proliferation, differentiation, migration, and apoptosis

Epidermal growth factor receptor (EGF R), a transmembrane glycoprotein, is a member of the ErbB receptor tyrosine kinase family. Upon ligand binding, EGF R undergoes dimerization. Specific tyrosine residues in the cytoplasmic domain are subsequently phosphorylated, and adaptor proteins and enzymes are recruited to transmit signals from EGF R via signaling pathways to the nucleus. This regulates diverse biological functions like cell proliferation, differentiation, migration, and apoptosis (Morandell et al. 2008; Yarden and Sliwkowski 2001).

An important signaling pathway downstream of EGF R is RAS/RAF. The adaptor protein growth factor receptor-bound protein 2 (Grb2) complexes with son of sevenless (SOS) associating with EGF R, either directly or through binding to SHC-transforming protein 1 (SHC1) (Waters et al. 1996). SOS mediates the activation of RAS proteins (Downward 1996). Activated RAS recruits and activates RAF family kinases promoting activation of extracellular signal-regulated kinase (ERK) mediated through mitogen activated protein kinase 1 (MEK). Activated kinases move to the nucleus and regulate transcription factors involved in cell proliferation (Liebmann 2001). 

The PI3K/AKT cascade is another important target in EGF R signaling (Stover et al.1995). Activated phosphoinositide 3-kinase (PI3K) phosphorylates and activates protein kinase B (AKT), leading to phosphorylation of mammalian target of rapamycin (mTOR). Subsequent phosphorylation of ribosomal protein S6 kinase beta-1 (P70S6K) promotes protein synthesis.

ErbB family members play an important role in the development and malignancy of various human cancers (Mishra et al. 2017). Kinase mutations and/or overexpression of the receptor can result in deregulation in signaling networks; understanding the precise roles of the EGF R-mediated signaling pathways is crucial for translating these findings into new cancer therapies. 


Interactive Epidermal Growth Factor Receptor Pathway Poster

We have compiled key antibodies involved in the EGF R signaling pathway into one handy poster you can download for your reference. 

Click the pathway components within the images below to discover the key antibodies that Bio-Rad provides.

Sorry, there is a problem

Sorry, there is a problem

We experienced a problem while serving your page, please try again shortly.

Could not find database in connection string.

Server Error in '/' Application.

Could not find database in connection string.

Description: An unhandled exception occurred during the execution of the current web request. Please review the stack trace for more information about the error and where it originated in the code.

Exception Details: System.Exception: Could not find database in connection string.

Source Error:

An unhandled exception was generated during the execution of the current web request. Information regarding the origin and location of the exception can be identified using the exception stack trace below.

Stack Trace:


[Exception: Could not find database in connection string.]
   ukplc.Data.DatabaseEL.get_DatabaseName() +180
   ukplc.Data.Wrapper.CommandWrapper.ExecuteDataSet() +229
   CloudBuy.Sites.Core.Company.LoadCompanyFromDatabase() +325
   CloudBuy.Sites.Core.Company.LoadCompany() +105
   Sites.Sitehead.FetchCompany() in /builds/bio-rad-antibodies/applications/sites/Sites/Sites/Code/Sitehead.cs:185
   Sites.Sitehead.OnPreLoad(EventArgs e) in /builds/bio-rad-antibodies/applications/sites/Sites/Sites/Code/Sitehead.cs:163
   System.Web.UI.Page.ProcessRequestMain(Boolean includeStagesBeforeAsyncPoint, Boolean includeStagesAfterAsyncPoint) +3628


Version Information: Microsoft .NET Framework Version:4.0.30319; ASP.NET Version:4.8.4770.0

Antibodies against targets involved with EGF R Signaling

    DescriptionSpecificityTargetFormatHostIsotypeClone Applications Citations Product Type Code Validation Types

    References:

    • Downward J (1996). Control of ras activation. Cancer Surv 27, 87-100.
    • Liebmann C (2001). Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal 13(11), 777-85.
    • Mishra R et al. (2017). Genomic alterations or ERBB receptors in cancer: clinical implications. Oncotarget 8(69), 114371-114392.
    • Morandell S et al. (2008). Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 8(21), 4383-401.
    • Stover DR et al. (1995). Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem 270, 15591-7.
    • Waters SB et al. (1996). Insulin and epidermal growth factor receptors regulate distinct pools of Grb2-SOS in the control of Ras activation. J Biol Chem 271(30), 18224-30.
    • Yarden Y and Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-37.